Pfizer, Inc. (PFE) Stock Price & How to Invest

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

The 2026 picture so far: revenue over the trailing twelve months is about $63.7 billion, and second quarter 2026 revenue of about $15.0 billion rose roughly 2.6% year over year, while adjusted EPS of $0.77 beat the $0.68 consensus, Pfizer's fourth straight beat. GAAP net income is much lower (about $4.3 billion over the trailing year, after a loss in the fourth quarter of 2025), which is why the trailing P/E looks high at about 39x while the forward P/E is near 10x. Free cash flow was about $12.5 billion. In October 2026 Pfizer secured an expanded FDA approval for Tukysa as a chemotherapy-free maintenance option in HER2-positive metastatic breast cancer. The stock closed at about $29.58 on October 16, 2026, up roughly 17.5% year to date and 22% over one year, near the top of its 52-week range of about $23.60 to $29.90. Third quarter results are scheduled for November 3, 2026, with consensus near $0.73 of EPS on about $15.9 billion of revenue.

Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. Analysts' consensus as of October 2026 has revenue slipping to about $62.2 billion in 2026 and $59.9 billion in 2027, with EPS of roughly $2.96 and $2.89, so earnings are expected to drift lower rather than grow. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt (total debt is about $63.5 billion against $11.7 billion of cash), and large acquisitions carry integration and return risk. The dividend exceeds GAAP earnings (a payout above 200% on trailing GAAP EPS), so it leans on adjusted earnings and cash flow. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.

26 analysts publish price targets on PFE, averaging $29.26 against a $29.58 price as of October 2026, or -1.1%. The published targets run from $25.00 to $36.00, a moderate spread, and the ratings split 10 buy, 16 hold, 2 sell. Over the last six months there have been 4 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PFE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Pfizer, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Oncology expansion via Seagen. Pfizer made oncology a strategic priority and acquired Seagen to add antibody-drug conjugate technology and a cancer pipeline. The most optimistic published target, $36.00, assumes this works close to its best case.

The case against. Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. The most pessimistic target, $25.00, is roughly what PFE is worth if this bites instead.

Read the full bull and bear case on PFE, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Pfizer, Inc. (PFE) has had one share split in the last 10 years:

• 1054:1000 on November 17, 2020, so every share held became 1.054 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of PFE the day before the 1054:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Pfizer, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$63.7 billion (Q2 2026 +~2.6% YoY)
• Operating margin: ~28%
• Net income (TTM, GAAP): ~$4.3 billion
• Q2 2026 adjusted EPS: ~$0.77 vs ~$0.68 consensus
• P/E (trailing / forward): ~39x / ~10x
• Dividend yield: ~5.8% ($1.72/yr)
• Market cap: ~$169 billion
• Debt / cash: ~$63.5 billion / ~$11.7 billion

Pfizer trades at about 10x forward earnings and a dividend yield near 5.8%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges rather than weak operations. Even after a 17.5% gain in 2026 the shares sit right around the 26 analysts' mean target of about $29, so the valuation now balances substantial cash generation against flat-to-lower consensus earnings.

If you want PFE exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses PFE naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to PFE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PFE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (SPHD, DVY, VLUE), which spreads the position across many companies. Or build it into a focused thematic portfolio, so PFE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PFE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Pfizer (PFE) is a cash-generative, high-yield pharma navigating a post-COVID reset, using its Seagen-led oncology push, pipeline, and acquisitions to offset products losing exclusivity later this decade. The stock has rallied in 2026 (up about 17.5% year to date as of mid-October) after four straight quarterly EPS beats, with third quarter results due November 3. In a portfolio it behaves as a defensive healthcare and dividend-income anchor, with drug-pricing policy, patent expirations, and COVID-revenue volatility as the main swing factors.

Whether PFE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PFE a buy or a sell?, and where the stock could go from here in the PFE stock forecast.

For income investors, whether PFE pays a dividend and how the payout looks is covered in does PFE pay a dividend? And to weigh PFE against a peer, read the full side-by-side comparisons: PFE vs LLY and PFE vs AMGN.